Ironwood Pharma (IRWD) Tops Q2 EPS by 12c, Updates Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.34, $0.12 better than the analyst estimate of $0.22. Revenue for the quarter came in at $104.1 million versus the consensus estimate of $93.1 million.

GUIDANCE:

Ironwood Pharma sees FY2021 revenue of $390-410 million, versus the consensus of $392 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• JPMorgan Double Upgrades Salzgitter AG (SZG:GR) (SZGPY) to Overweight
• RBC Capital Downgrades Wizz Air Holdings (WIZZ:LN) (WZZAF) to Underperform